Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids
- 26 July 2012
- journal article
- Published by American Society of Hematology in Blood
- Vol. 120 (4), 891-899
- https://doi.org/10.1182/blood-2011-11-393371
Abstract
Recombinant factor VIIa (rFVIIa) is used for treatment of hemophilia patients with inhibitors, as well for off-label treatment of severe bleeding in trauma and surgery. Effective bleeding control requires supraphysiological doses of rFVIIa, posing both high expense and uncertain thrombotic risk. Two major competing theories offer different explanations for the supraphysiological rFVIIa dosing requirement: (1) the need to overcome competition between FVIIa and FVII zymogen for tissue factor (TF) binding, and (2) a high-dose–requiring phospholipid-related pathway of FVIIa action. In the present study, we found experimental conditions in which both mechanisms contribute simultaneously and independently to rFVIIa-driven thrombin generation in FVII-deficient human plasma. From mathematical simulations of our model of FX activation, which were confirmed by thrombin-generation experiments, we conclude that the action of rFVIIa at pharmacologic doses is dominated by the TF-dependent pathway with a minor contribution from a phospholipid-dependent mechanism. We established a dose-response curve for rFVIIa that is useful to explain dosing strategies. In the present study, we present a pathway to reconcile the 2 major mechanisms of rFVIIa action, a necessary step to understanding future dose optimization and evaluation of new rFVIIa analogs currently under development.Keywords
This publication has 46 references indexed in Scilit:
- Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patientsJournal of Thrombosis and Haemostasis, 2010
- Identifying non‐responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definitionHaemophilia, 2010
- Evidence supporting the use of recombinant activated factor VII in congenital bleeding disordersDrug Design, Development and Therapy, 2010
- Analysis of factor VIIa binding to relipidated tissue factor by surface plasmon resonanceBlood Coagulation & Fibrinolysis, 2010
- Tissue Factor in CoagulationArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distributionBlood Coagulation & Fibrinolysis, 2008
- The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosisBlood, 2008
- Caution in the interpretation of continuous thrombin generation assaysJournal of Thrombosis and Haemostasis, 2007
- Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society RegistryHaemophilia, 2005
- Response: Mechanism of Action of High-Dose Factor VIIaArteriosclerosis, Thrombosis, and Vascular Biology, 2003